Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 4/20 | 0.56 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.50 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.50 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | PGR | P06401 | 4/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | CMA1 | P23946 | 2/20 | 0.43 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15170865 | 0.86 | AHR (0.57) | AHRGRIA1CACNG8PDE3BPDE3A | |
| SCHEMBL12336061 | 0.85 | AHR (0.49) | AHRGRIA1CACNG8PDE3BPDE3A | |
| SCHEMBL433708 | 0.76 | AHR (0.61) | AHRGRIA1CACNG8PDE3BPDE3A | |
| SCHEMBL1556955 | 0.74 | GAA (0.60) | AHRGRIA1CACNG8PDE3BPDE3A | |
| SCHEMBL23788017 | 0.72 | AHR (0.61) | AHRGRIA1CACNG8PDE3BPDE3A | |
| SCHEMBL5535534 | 0.72 | AHR (0.61) | AHRGRIA1CACNG8PDE3BPDE3A | |
| SCHEMBL2468488 | 0.72 | AHR (0.61) | AHRGRIA1CACNG8PDE3BPDE3A | |
| SCHEMBL1459491 | 0.72 | TDP2 (0.62) | AHRGRIA1CACNG8PDE3BPDE3A | |
| SCHEMBL12427789 | 0.72 | AHR (0.61) | AHRGRIA1CACNG8PDE3BPDE3A | |
| SCHEMBL19391 | 0.72 | AHR (0.67) | AHRGRIA1CACNG8PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9539239-B1 | Compositions and methods for treatment of neurodegenerative disease | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2017-01-10 | — | — | US | disclosed |
| US-9539239-B1 | Compositions and methods for treatment of neurodegenerative disease | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2017-01-10 | — | — | US | disclosed |
| US-20160367527-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-12-22 | — | — | US | disclosed |
| US-20160367527-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-12-22 | — | — | US | disclosed |
| US-9162981-B2 | Compositions and methods for treatment of neurodegenerative disease | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-10-20 | — | — | US | disclosed |
| US-20130217679-A1 | Compositions and Methods for Treatment of Neurodegenerative Disease | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217679-A1 | Compositions and Methods for Treatment of Neurodegenerative Disease | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-08-22 | — | — | US | disclosed |
| WO-2011119777-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-09-29 | — | — | WO | disclosed |
| EP-0912557-B1 | OXINDOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-07-09 | — | — | EP | disclosed |
| US-6265411-B1 | ANGIOGENESIS INHIBITOR | ZENECA LIMITED (GB) | 2001-07-24 | — | — | US | disclosed |
| EP-0912557-A1 | OXINDOLE DERIVATIVES | ZENECA LIMITED (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997042187-A1 | OXINDOLE DERIVATIVES | ZENECA LIMITED (GB) | 1997-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367527-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASE | CLN6, PSEN2, CHAT | AHR 3990/4885GRIA1 1274/4885CACNG8 2691/4885 |
| US-20130217679-A1 | Compositions and Methods for Treatment of Neurodegenerative Disease | CLN6, PSEN2, CHAT | AHR 3990/4885GRIA1 1274/4885CACNG8 2691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.